JCAD

Across TCGA pan-cancer cohorts, JCAD Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated JCAD data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher JCAD Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated JCAD expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

CESC, LGG, and OV are the cancer types where JCAD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	IV	0.053	0.529	<.001	6	view →
LGG	OS	Median	All	0.396	0.831	.017	6	view →
OV	OS	Median	III,IV	0.312	0.685	.005	6	view →
UCEC	DFS	Median	All	0.779	0.628	.031	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUAD	OS	Median	III,IV	0.235	0.677	.030	3	view →
COAD	OS	Median	III,IV	0.142	0.565	.035	3	view →
SKCM	DFS	Median	II,III,IV	0.715	0.531	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

JCAD–CESC (DFS)

Open the CESC breakdown →